Actuate Therapeutics
A survival signal without cash flow: promising science, unacceptable predictability for our style
Actuate Therapeutics is a clinical-stage oncology company advancing elraglusib, a first-in-class GSK‑3β inhibitor.
The company reported a statistically significant overall survival benefit in a randomized Phase 2 trial in first‑line metastatic pancreatic ductal adenocarcinoma when elraglusib was added to gemcitabine/nab‑paclitaxel, with median OS of 10.1 months versus 7.2 months (HR 0.62) and a doubling of one‑year survival, now published in Nature Medicine and reflected in the 2025 10‑K.
The FDA has granted Fast Track designation in pancreatic cancer, and elraglusib carries multiple orphan drug designations.
In May 2026 the FDA cleared an IND for an oral elraglusib program, with a Phase 1/2 start planned for 2H 2026. These are encouraging scientific milestones that could justify a pivotal program, but they do not yet translate into durable, predictable cash flows required by quality‑value criteria.
Financially, Actuate has no product revenue, a TTM operating cash outflow of roughly 19.6 million dollars through March 31, 2026, and just 8.1 million dollars of cash at quarter‑end, with management disclosing runway only into July 2026 and a going‑concern warning.
The company relies on an at‑the‑market facility up to 100 million dollars and a 50 million dollar committed equity facility, implying further dilution risk. Drug substance is currently manufactured in China, a supply‑chain and geopolitical risk explicitly noted in filings.
In a world where first‑line PDAC standards now include NALIRIFOX (Onivyde regimen), any new regimen must show clear, durable, and regulator‑accepted benefit across relevant subgroups and geographies. On our quality‑value checklist this is not yet an ownable business.
Does Actuate Therapeutics have a strong competitive moat?
We dissect potential moat components recognizing there is no approved product yet. Intangible assets: 45/100. Composition‑of‑matter coverage for elraglusib polymorphs (multiple US and ex‑US grants) that expire around 2038, plus Fast Track in PDAC and several US orphan designations, provide time‑limited protection if approved. Weight 40%.
Switching costs: 10/100. Oncologists can change regimens; without guideline inclusion and multi‑year outcomes data, stickiness is low. Weight 25%. Network effects: 0/100. No two‑sided network or data moat today. Weight 10%.
Cost advantage: 5/100. Semi‑virtual model with single‑source DS manufacturing in China and no long‑term supply contracts implies no structural cost edge. Weight 15%. Efficient scale: 10/100. If approved for rare pediatric indications, market scale may limit entrants, but PDAC is competitive and capital intensive. Weight 10%.
Weighted result ≈ 23/100. Overall, the moat is only a possibility pending regulatory success and commercialization.
Does Actuate Therapeutics have pricing power in its industry?
Oncology therapies with survival benefit typically command strong pricing relative to cost of care. If elraglusib is ultimately approved, especially with orphan or pediatric rare‑disease incentives, pricing power could be meaningful.
However, PDAC first‑line therapy now includes the NALIRIFOX (Onivyde) regimen, and any elraglusib combination must show clear incremental value versus established standards to maintain price and access. Until confirmatory data and payer negotiations are known, pricing power remains latent rather than demonstrated.
How predictable is Actuate Therapeutics's business?
Actuate has no recurring revenue and depends on clinical, regulatory, and financing milestones. While the Phase 2 PDAC result is encouraging and peer‑reviewed, the company must still align with regulators on a registrational strategy and execute at scale. Oral elraglusib introduces additional formulation and dose‑exposure risks.
Competitive dynamics and payer responses further reduce visibility. This profile does not meet our preference for steady, recurring, and geographically diversified cash flows.
Is Actuate Therapeutics financially strong?
As of March 31, 2026, cash and equivalents were 8.1 million dollars with a disclosed runway only into July 2026 and a stated going‑concern warning. TTM net cash used in operations is approximately 19.6 million dollars (2025 operating cash outflow of 19.2 million plus Q1‑26 outflow of 5.0 million minus Q1‑25 outflow of 4.6 million).
The firm relies on an ATM facility up to 100 million dollars and a 50 million‑dollar committed equity facility, signaling likely dilution. Balance sheet liabilities are modest (notably a UIC license payable), but financing risk is high.
How effective is Actuate Therapeutics's capital allocation strategy?
Capital has funded clinical development and public listings rather than producing returns yet. 2025 operating cash outflow was about 19.2 million dollars, and Q1‑26 outflow was 5.0 million dollars.
General and administrative expense rose in 2025 largely from stock‑based compensation and public‑company costs, and the company raised equity via a 2025 public offering, private placement, committed equity facility, and ATM.
We recognize that development‑stage biotech must invest ahead of revenue, but dilution and limited runway weigh on this score.
Does Actuate Therapeutics have high-quality management?
CEO Daniel M. Schmitt has led the company since before its 2024 IPO; COO Andrew P.
Mazar and CFO Paul Lytle bring development and financing experience; industry veteran Martin Huber, MD joined the board in May 2026. Nevertheless, the team has not yet commercialized a product at Actuate, stock‑based compensation is material, and execution risk remains high.
Major holder BIOS/Bios Equity Partners owns a significant stake, aligning some incentives but also concentrating control.
Is Actuate Therapeutics a quality company?
Actuate Therapeutics is a poor quality company with a quality score of 24/100
- Randomized Phase 2 in first‑line mPDAC met OS endpoint and is peer‑reviewed; Phase 3 planning and oral formulation IND cleared, but no regulatory approvals yet.
- Zero revenue, negative TTM free cash flow, and runway only into July 2026 force reliance on dilutive financing vehicles.
- IP protection around elraglusib polymorphs runs to 2038 with potential PTE; Fast Track and multiple orphan designations add time‑limited regulatory advantages.
- Manufacturing of drug substance in China and absence of long‑term supply agreements add execution and geopolitical risks.
- Competitive bar in first‑line PDAC has risen with FDA approval of NALIRIFOX; broad adoption would require compelling, confirmatory data and payer acceptance.
What is the fair value of Actuate Therapeutics stock?
Is Actuate Therapeutics a good investment at $2.00?
The following analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. The opinions expressed are based on publicly available information and historical data. Beanvest and its contributors may hold positions in the securities mentioned. Investors should conduct their own due diligence or consult a licensed financial advisor before making any investment decision.